AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...

Global equity funds attracted significant inflows in the week ending February 12, after a Bank of England rate cut drove a ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

The Telegraph has been shortlisted for 18 honours at this year’s Press Awards, including daily and Sunday newspapers of the year ...

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...